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Abstract
Background: The pathophysiology of heart failure with preserved ejection fraction
(HFpEF) is complex and multifactorial. Chronotropic incompetence (ChI) has emerged
as a crucial pathophysiological mechanism. Beta-blockers, drugs with negative chro-
notropic effects, are commonly used in HFpEF, although current evidence does not
support its routine use in these patients.
Hypothesis: We postulate beta-blockers may have deleterious effects in HFpEF and
ChI. This work aims to evaluate the short-term effect of beta-blockers withdrawal on
functional capacity assessed by the maximal oxygen uptake (peakVO2) in patients
with HFpEF and ChI.
Methods: This is a prospective, crossover, randomized (1:1) and multicenter study.
After randomization, the clinical and cardiac rhythm will be continuously registered
for 30 days. PeakVO2 is assessed by cardiopulmonary exercise testing (CPET) at
15 and 30 days in both groups. Secondary endpoints include quality of life, cognitive,
and safety assessment. Patients with stable HFpEF, functional class New York Heart
Association (NYHA) II-III, chronic treatment with beta-blockers, and ChI will be
Abbreviations: ChI, chronotropic incompetence; CPET, cardiopulmonary exercise testing; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with
reduced ejection fraction; NYHA, New York Heart Association; PeakVO2, peak exercise oxygen uptake; QoL, quality of life.
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enrolled. A sample size estimation [alfa: 0.05, power: 90%, a 20% loss rate, and delta
change of mean peakVO2: +1.2 mL/kg/min (SD ± 2.0)] of 52 patients is necessary to
test our hypothesis.
Results: Patients started enrolling in October 2018. As January 14th, 2020, 28 patients
have been enrolled. It is projected to enroll the last patient at the end of July 2020.
Conclusions: Optimizing therapy that improves functional capacity remains an
unmeet priority in HFpEF. Deprescribing beta-blockers in patients with HFpEF and
ChI seems a plausible intervention to improve functional capacity. This trial is an
attempt towards precision medicine in this complex syndrome.
Trial registration: ClinicalTrials.gov: NCT03871803.
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1 | INTRODUCTION
Heart failure (HF) with preserved ejection fraction (HFpEF) is a het-
erogeneous syndrome that is the predominant form of HF in western
countries.1-4 Chronotropic incompetence (ChI), defined as the inability
to increase heart rate during exercise adequately, is commonly pre-
sent (ranging from 20 to 75%) in HFpEF patients.5-11 Furthermore,
ChI has been proposed as a pathophysiologic mechanism associated
with poorer outcomes and decreased functional capacity in a sub-
group of patients with HFpEF.8,12,13
Data from current registries show a high proportion (ranging from
50% to 80%) of beta-blockers prescription in HFpEF patients regardless
of the heart rhythm.3,14 Nevertheless, there is no well-established evi-
dence endorsing the effect of beta-blockers. For instance, recent studies
suggested that patients with an ejection fraction of 50% or greater did
not see any benefits from receiving beta-blockers.15-17 Even more, the
evidence is missing stratifying patients with HFpEF across ChI status.
When ChI is present, beta-blockers may have negative effects on
functional capacity and other surrogates of the disease severity by
exacerbating the ChI. Thus, we hypothesize that deprescribing beta-
blockers in this particular scenario will translate into an improvement
in short-term maximal functional capacity. The purpose of this ran-
domized controlled study is to evaluate the short-term effects of
beta-blockers withdrawal on the functional capacity, cognitive func-
tion, and quality of life (QoL) in patients with HFpEF and
documented ChI.
The primary endpoint of the study is absolute and relative
changes in peak oxygen uptake (peakVO2) at 15-day after the inter-
vention. The secondary endpoints are: (a) 15-day absolute changes in
cognitive function assessed by the Mini-Mental State Examination
(MMSE) and Montreal Cognitive Assessment (MoCa); (b) 15-day abso-
lute changes in echocardiogram parameters (E/E' ratio and left atrial
volume index); (c) 15 days absolute changes in QoL assessed by Min-
nesota Living With Heart Failure Questionnaire (MLHF); and
(d) 15 days absolute and relative changes in prognostic biomarkers
(N-terminal pro-B-type natriuretic peptide -NT-proBNP- and serum
carbohydrate antigen 125-CA125-).
Safety endpoints include the composite event of the total number
of episodes of acute HF hospitalizations, total episodes of worsening
HF not requiring hospitalization or mortality at 6 months.
2 | METHODS
2.1 | Study design
This study is designed as a multicenter, prospective, controlled, ran-
domized, two-arms, cross-over, efficacy trial. The population includes
patients with the diagnosis of stable HFpEF according to criteria of
the European Society of Cardiology18 and New York Heart Associa-
tion functional (NYHA) class II-III/IV. A computer-generated randomi-
zation sequence previously designed will be used to allocate
participants (in a 1:1 ratio) to receive: (a) withdrawal of beta-blocker
followed by beta-blocker reintroduction in two periods of 15 days; or
(b) continuation of beta-blocker followed by beta-blocker withdrawal
in two periods of 15 days. A summary of the study design is described
in Figure 1. The study will be conducted in two centers in Spain. Dis-
counting the time due to staggered entry, the total duration of a
patient's follow-up will be 6 months. All patients will provide signed
informed consent before randomization. The research ethics commit-
tee approves the protocol of our center following the principles of the
Declaration of Helsinki and national regulations.
2.2 | Study population sampling
Candidate patients will be selected from the outpatient HF-clinics of the
Hospital Clínico Universitario of Valencia-Spain and Hospital Clínico
Universitario de Santiago-Spain. Treatment will be following current
guidelines18 and HF educational programs of each institution. Briefly,
2 PALAU ET AL.
HFpEF is defined as the presence of: (a) symptoms and signs of HF with
normal (≥50%) left ventricular ejection fraction (LVEF); (b) elevation of
natriuretic peptides; and (c) increase in LV wall thickness and/or
increased left atrial (LA) size as a sign of increased filling pressures. Inclu-
sion and exclusion criteria are summarized in Table 1. Inclusion criteria
require the presence of ChI after performing the cardiopulmonary exer-
cise testing (CPET). The chronotropic index is equal to (heart rate at peak
exercise−resting heart rate)/([220 – age] − resting heart rate).19 ChI is
defined as a chronotropic index <0.62.
2.3 | Intervention
2.3.1 | Eligibility assessment and screening visit
After reviewing the inclusion/exclusion criteria and signing the
informed consent form, a comprehensive medical history, physical
examination, anthropometry, and examination tests will be performed
by two blinded cardiologists to patients' allocation groups. The exami-
nation tests will include an electrocardiogram (ECG), two-dimensional
transthoracic echocardiography, CPET, cognitive assessment by
MMSE and MoCa, QoL assessment by MLHF, continuous ECG
recording during the first 30-day and blood samples for a panel of
baseline biomarkers.
Finally, if the patients fulfill all the inclusion criteria (including ChI
assessed by CPET) and any exclusion criteria (including a valid CPET
without signs of ischemia), are randomized in a 1:1 ratio to one of
the following interventions: (a) A-arm: beta-blockers withdrawal; or
(b) B-arm: beta-blockers continuation.
2.3.2 | Treatment intervention and visits
Following screening (visit 0) and randomization (visit 1) visits, the pro-
cedures across treatment arms are:
-A-arm: Patients allocated to this arm are instructed to reduce by
half the dose of beta-blocker (Figure 1). The patients will be advised
for potential adverse effects and instructed to contact with outpa-
tient's clinics of HF if any adverse effect occurs. Patients will be
checked in 3 days (visit 2) by a cardiologist. If clinically stable, the
patients are instructed to withdraw the beta-blocker and repeat all
the procedures of the study at 15 days (visit 3). After visit 3, the
F IGURE 1 Flow chart for patient
inclusion and follow up. BB, beta-blockers
TABLE 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Stable symptomatic heart failure
(NYHA functional class ≥II)
during the last month.
Inability to perform a valid
baseline exercise test
Diagnosis criteria of HFpEF
according to ESC guidelines:
(a) symptoms and signs of HF
(b) left ventricular ejection
fraction >50% by Simpson
method
(c) NT-proBNP >125 pg/mL in
the last month
(d) at least one additional
criterion: 1. relevant structural
heart disease (LVH and/or
LAE); and/or 2. diastolic
dysfunction
Significant primary pulmonary
disease; including pulmonary
arterial hypertension, chronic
thromboembolic pulmonary
disease or chronic obstructive
pulmonary disease
Patient with prior history of left
ventricular ejection fraction
<50%
History of an acute coronary
syndrome in the previous
12 months
Adults >18 years old Effort angina or signs of ischemia
during CPET
Previous admission for acute
heart failure
Significant primary moderate to
severe valvular disease
Previous treatment with beta-
blockers during the last
3-month
Any other comorbidity with a life
expectancy lower than 1 year
Chronic treatment with digitalis or
calcium channel blockers
Chronotropic incompetence
assessed by CPET, defined as:
[(HRmax − HRrest)]/[(220 −
age) − (HRrest)] < 0.62
HR at rest >75 bpm
Uncontrolled blood pressure,
defined as systolic blood
pressure > 140 mmHg and/or
diastolic blood
pressure > 90 mmHg.
Abbreviations: CPET, cardiopulmonary exercise testing; ESC, European
Society of Cardiology; HF, heart failure; HFpEF, heart failure with
preserved ejection fraction; HRmax, heart rate at maximum effort; HRrest,
heart rate at rest; LAE, left atrial enlargement; LVH, left ventricular
hypertrophy; NT-proBNP, N-terminal prohormone of brain natriuretic
peptide; NYHA, New York Heart Association.
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patients initiate the previous half dose of beta-blockers. Patients are
visited at 18 days (visit 4). If clinically stable, the patient will increase
to the previous dose of the beta-blocker and repeat all the examina-
tion tests at 30 days (visit 5).
-B-arm: Patients allocated to this arm will continue with the same
treatment and revisited 3 days after (visit 2) (Figure 1). All of the study
procedures repeated at 15 days (visit 3), and, after them, the patients
are instructed to reduce by the half dose of beta-blocker. Likewise,
the patients are advised for potential adverse effects and instructed
to contact outpatient HF-clinics of HF if any adverse effect occurs.
Patients are revisited in 3 days (at 18 days, visit 4), and if clinically sta-
ble, the patient withdraws the beta-blocker and repeats all the exami-
nation tests at 30 days (visit 5).
At visit 5, the responsible cardiologist will assess all the
examination test and individually decide the convenience of
beta-blockers reintroduction or withdrawal in both arms. A cardi-
ologist of the HF-unit will clinically evaluate all patients at
60-day after randomization (visit 6). Additional visits will be per-
mitted according to the patient's clinical status and will be
registered.
2.4 | Study procedures
A scheme of procedures along the visits is presented in Figure 1.
2.4.1 | Cardiopulmonary exercise testing
Maximal functional capacity is evaluated with an incremental and
symptom-limited cardiopulmonary exercise testing (CORTEX
Metamax 3B) on a bicycle ergometer, beginning with a workload
of 10 W and increasing gradually in a ramp protocol at 10-W
increments every 1 minute. We define maximal functional capac-
ity when the patient stops pedaling because of symptoms, and
the respiratory exchange ratio (RER) is ≥1.05. During exercise,
patients will be continuously monitored with 12-lead electrocar-
diogram and blood pressure measurements every 2 minutes. Gas
exchange data and cardiopulmonary variables are averaged every
10 seconds values. PeakVO2 is considered the highest value of
VO2 during the last 20 seconds of exercise. The VE/VCO2 slope
is determined by measuring the slope across the entire course of
exercise.20 Each subject will undergo three tests (at baseline,
15 days, and 30 days).
2.4.2 | Echocardiography
Two-dimensional Doppler echocardiogram is performed under resting
conditions. Each subject will undergo three examinations (at baseline,
15 days, and 30 days). All parameters, including tissue Doppler param-
eters, are measured according to current guidelines of the European
Society of Echocardiography.21
2.4.3 | Cognitive assessment by MMSE and MoCa
MMSE and MoCa tests will be used to assess the cognitive abilities
and evaluate the impact of the intervention on cognitive function.22
Each subject will undergo three tests (at baseline, 15 days, and
30 days). Overall scores will be analyzed.
2.4.4 | Health-related QoL
MLHF questionnaire23 will be used to assess the impact of the inter-
vention on QoL. Each subject will undergo three tests (at baseline,
15 days, and 30 days).
2.4.5 | Continuous ECG recording
The heart rhythm and rate are continuously recorded during 30 days
by remote monitoring systems integrated into clothing (Nuubo Suite
License).
2.4.6 | Serum biomarkers
Three blood samples (at baseline, 15 days, and 30 days) are collected
under standardized conditions for biomarkers' profiling. Prognostic
biomarkers in HF will be analyzed,24 NT-proBNP and CA125 will be
measured by electrochemiluminescence immunoassay.
2.5 | Sample size calculation
The null hypothesis of the study is that the mean peakVO2 absolute
differences from baseline to 15 days after the withdrawal of beta-
blockers will be similar. The sample size determination for this study
assumes two-sided testing at the 0.05 significance alpha level.
Because this is a randomized clinical trial, we assume no differences in
peakVO2 at baseline among the two arms. Based on a prior study of
our group in HFpEF, we assume eligible patients will have a mean
(SD) peakVO2 of 10 ± 2.8 mL/kg/min.8 Along the same line, and
based on prior studies about the deleterious effects of heart rate
slowing in HFpEF patients, we speculate a blocker withdrawal will
increase peak VO2 about 10%. With this data in mind, we assume a
mean change of 1.2 mL/kg/min and a common SD of 2.0,8,25,26 a clini-
cal meaningful change according a recent HFA position paper that
consider significant clinical changes of peakVO2 those greater than
6% when baseline peakVO2 is lower than 14 mL/min/1.73 m2.27
Assuming an allocation ratio of 1:1, a total of 42 patients
(21 patients per group) would provide 90% of power at a significance
alpha level < 0.05. Assuming 20% of withdrawals or losses to follow-
up, a total of 26 patients per arm (52 patients) will be enrolled. The
software used for sample size calculation was “xsampsi” from
Stata 14.1.
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2.6 | Statistical plan
Continuous variables will be presented as mean ± SD or median
(interquartile range—IQR) as appropriately; categorical variables as
percentages. All statistical comparisons will be made under the
intention-to-treat principle. A repeated-measures analysis of variance
(ANOVA) will be used for the comparisons of continuous outcomes
among the two-intervention groups. The interaction group*time-
points will be tested to unveil any effect of time (15 and 30 days) on
the magnitude of the intervention. Only in the event of imbalance in
baseline characteristics, repeated-measures analysis of covariance
(ANCOVA) will be used. A two-sided P-value of <0.05 will be consid-
ered to be statistically significant for all analyses. All analyses will be
performed with Stata 14.1.
3 | RESULTS: CURRENT STATUS
The ethics committee approved the protocol of our center, following
the principles of the Declaration of Helsinki and national regulations.
The protocol is registered at EudraCT (2017-005077-39) and
ClinicalTrials.gov (NCT03871803). Patients started enrolling in
October 2018. As of January 14th, 2020, a total of 28 were enrolled.
We expect to finish the inclusion at the end of July 2020.
The median (IQR) age of patients included is 74.3 (68-77) years,
19 (67.9%) are women, and 28 (100%) were previously admitted for acute
heart failure. Median (IQR) of NT-proBNP is 922 (397-2016) pg/mL.
4 | DISCUSSION
4.1 | Background and rationale
HFpEF is a complex and heterogeneous clinical syndrome character-
ized by exercise intolerance, markedly reduced functional
capacity,28,29 normal left ventricular ejection fraction (>50%), and evi-
dence of diastolic dysfunction and left atrial enlargement.18 Despite
being a contemporary challenge, the pathophysiological mechanisms
of impaired exercise capacity and poor quality of life in these patients
are not yet entirely clarified.30,31 Among cardiac mechanisms, ChI has
been proposed as a pathophysiologic mechanism associated with
poorer exercise capacity in a subgroup of patients with HFpEF.6-8
Along this same line, recent evidence has shown that ChI is frequently
present (ranging from 20% to 75%) in HFpEF patients.5-11
From epidemiological perspective, patients with HFpEF are usu-
ally older, predominantly females and with high prevalence of other
cardiovascular comorbid conditions such as atrial fibrillation, hyper-
tension, and renal dysfunction1-4 which in the end contribute to
reduced exercise tolerance, and may explain the high proportion
(ranging from 50% to 60%) of beta-blockers prescription in HFpEF
patients.3,4,14 Nevertheless, emerging evidence suggests that pharma-
cological heart rate lowering is not beneficial in patients with pre-
served ejection fraction.15-17 In this regard, the proposed
pathophysiological mechanism of pharmacological heart rate lowering
in HFpEF patients is the prolongation of the filling of the cardiac
chambers, which increases filling pressures, left ventricular diastolic
wall stress and central arterial pressures.12
To date, there is no convincing evidence to support the beneficial
effects of beta-blockers prescription in HFpEF patients.32-36 A recent
meta-analysis suggests a clinically beneficial effect of beta-blockers in
patients with HF and left ventricular ejection fraction ≥40%; however,
the evidence to those with left ventricular ejection fraction >50% is
limited.37 Recently, a recent secondary study from TOPCAT showed
that for patients with an EF of 50% or greater, beta-blocker use was
associated with an increased risk of HF hospitalizations but not CVD
mortality.15 However, no prior randomized clinical trial has explored
the effects of beta-blocker withdrawal on functional capacity in
HFpEF patients with documented ChI.
4.2 | Biological plausibility
Currently, no study has evaluated the acute hemodynamic effects of
beta-blockers in HFpEF.17 However, clinical experience with these
agents provides some insights. In this sense, some authors have
suggested that prolonged diastolic filling related to heart rate lowering
increases ventricular pressures in HFpEF patients.17,38 Interestingly,
beta-blocker cessation would translate into a reduction in end-
diastolic pressures, as has been recently suggested with a decrease in
natriuretic peptides following beta-blockers withdrawal.38
Another potential beneficial effects of beta-blockers withdrawal
on HFpEF patients with ChI stand out: (a) increase in heart rate
response during exercise which may be considered as a compensatory
mechanism for maintaining cardiac output in patients with significant
diastolic dysfunction; and (b) amelioration of delayed memory retrieval
in cognitively impaired patients,39 and (c) attenuation arterial central
pressures at rest and during exercise.12
4.3 | Feasibility and future implications
HFpEF is a heterogeneous syndrome in which no pharmacological
therapy has shown promising results. Identifying those HFpEF
patients with ChI could help us to characterize the different pheno-
types of this syndrome and optimize medical treatment. In this regard,
beta-blockers withdrawal could represent a treatment option in those
patients with documented ChI. This strategy is an attempt to move
forward into precision medicine in HFpEF by identifying the ChI phe-
notype and treating it accordingly.
5 | CONCLUSION
To date, there is no evidence about the benefit of beta-blockers in
HFpEF patients, even less in those with documented ChI. In this ran-
domized controlled trial, we aim to evaluate the effects of beta-
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blocker withdrawal on short-term functional capacity in stable HFpEF
patients.
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